or Try an Advanced Search...

    ETF Components for HRTS - Tema Cardiovascular and Metabolic ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    AMGN D -0.18 7.09
    LLY D 0.75 5.52
    ALNY C -1.63 5.30
    VRTX D -1.62 4.45
    NVO F -1.30 4.43
    BBIO F 1.13 4.07
    RARE C -1.70 3.47
    CYTK F 0.02 3.32

    Represented by ETF Holdings

    Keywords: Biopharmaceutical Amyloid Biotechnology Clinical Development Life Sciences Neuroscience Obesity Pharmaceutical Products S&P 500 Amyloidosis Cholesterol Diabetes Dysfunction Growth Hormone Hyperplasia IBD 50 Inflammation Monoclonal Antibody Myopathy Nasdaq 100
    Industries: Biotechnology Drug Manufacturers - Major

    Recent News for Tema Cardiovascular and Metabolic ETF & its Holdings

    Date Stock Title
    Oct 2 LLY Jim Cramer Remains Steadfast On Eli Lilly and Company (NYSE:LLY)
    Oct 2 CYTK Cytokinetics to Host Investor & Analyst Day on October 16, 2024
    Oct 2 LLY Eli Lilly to Invest $4.5 Billion to Open New Drug Manufacturing, Development Center
    Oct 2 NVO European Equities Close Mostly Higher in Wednesday Trading; Euro Area Unemployment Unchanged in August
    Oct 2 LLY Drugmaker Lilly slates another $4.5B for manufacturing and drug development improvements
    Oct 2 LLY Here's Why You Should Consider Buying Jazz Pharmaceuticals' Stock
    Oct 2 NVO Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
    Oct 2 LLY Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
    Oct 2 LLY Eli Lilly Building $4.5B Pharmaceutical Factory in Indiana
    Oct 2 ALNY Here's Why You Should Add ALNY Stock to Your Portfolio Right Now
    Oct 2 NVO Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn’t a Problem.
    Oct 2 LLY Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn’t a Problem.
    Oct 2 LLY Eli Lilly Plans $4.5 Billion Research Hub
    Oct 2 LLY Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries
    Oct 2 NVO Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries
    Oct 2 LLY Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries
    Oct 2 LLY Eli Lilly is building a $4.5 billion factory to speed up drug production
    Oct 2 LLY Eli Lilly announces $4.5B production/R&D site in Indiana
    Oct 2 LLY Lilly to invest $4.5 billion on new Indiana facility
    Oct 2 LLY Lilly to invest $4.5B on new Indiana facility
    Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions. The fund advisor generally is expected to consist of more than 15 companies but not more than 100 companies. The fund is non-diversified.
    Investment Management Cardiovascular Disease Metabolic Disease Treatment Of Cardiovascular Diseases
    Back to the Main HRTS Page...